Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

NEW YORK, July 23, 2019 /PRNewswire/ -- Xylyx Bio, a pioneer in physiomimetic biomaterials, today announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies.

As part of continuing efforts to incentivize companies to invest in new technology development in the United States, ARMI brings together a consortium of partners from across industry, government, academia and the non-profit sector to advance manufacturing processes and technologies for cells, tissues and organs. According to ARMI, approximately $80 million from the federal government is combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities.

"When developing bio-inspired replacement tissues, three-dimensional (3D) biomaterial scaffolds play a critical role in new tissue morphogenesis through interaction with human cells," said  Andrea Nye, Chief Executive Officer, Xylyx Bio, adding, "To this end, Xylyx Bio offers a variety of tissue-specific extracellular matrix (ECM) biomaterials that support regenerative medicine products and tissue engineering, including skin, bone, cartilage, and heart, among others."

Xylyx Bio's biomimetic 3D TissueSpec® ECM Scaffolds provide tissue-specific structure, architecture, topography and composition required for cell attachment and cell-cell communication in support of cell proliferation and differentiation for tissue regeneration. Xylyx Bio's ECM biomaterials can also be utilized in platforms such as 3D bioprinting, bioreactors and others.   

"Tissue-specific ECM products present the opportunity to plug into other advanced technologies, similar to the way microchips revolutionized the consumer electronics industry," stated Dr. John O'Neill, Co-founder and Chief Scientific Officer at Xylyx Bio. "By joining ARMI, Xylyx will be ideally positioned to work closely with other members towards integrating extracellular matrix as a bioactive class of biomaterials. We are thrilled to work with the ARMI consortium to offer our expertise in tissue-specific ECM biomaterials  to help accelerate the development of next generation products within the field of regenerative medicine."

About Xylyx Bio
Xylyx Bio specializes in native cell-specific substrates, providing the full suite of components from the natural cell microenvironment essential for the most accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine. To learn more, visit https://xylyxbio.com/.

Contact
Xylyx Bio, Inc.
Andrea Nye, CEO
[email protected]

SOURCE Xylyx Bio, Inc.